HP
SMMT icon

Havemeyer Place’s Summit Therapeutics SMMT Stock Holding History

Havemeyer Place’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.18M Buy
61,989
+55,735
+891% +$901K 0.14% 282
2025
Q4 		$109K Buy
+6,254
New +$118K 0.02% 464

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Havemeyer Place's SMMT Position: Q1 2026 in Review

Havemeyer Place increased its Summit Therapeutics (SMMT) stake by 891% in Q1 2026, buying an estimated $901K and bringing the position to 61,989 shares worth $1.18M. The position accounts for 0.14% of the portfolio, ranked #282.

Havemeyer Place first reported a position in SMMT in Q4 2025 and has held it in 2 quarters since. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

  • Havemeyer Place held 61,989 shares of Summit Therapeutics worth $1.18M as of Q1 2026.
  • Havemeyer Place bought 55,735 Summit Therapeutics shares in Q1 2026, an estimated $901K.
  • Summit Therapeutics made up 0.14% of Havemeyer Place's portfolio in Q1 2026, its #282 holding.
  • Havemeyer Place first reported a position in Summit Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on Havemeyer Place's 13F filing for Q1 2026, filed 13 May 2026.